Tofacitinib for Immune Skin Conditions in Down Syndrome

 

ID# NCT04246372

​

Recruitment Status:  recruiting as of August 2020.

 

Estimated Completion Date: August 2024

 

Sponsors and Collaborators: University of Colorado, Denver and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

​

Information provided by (Responsible Party): University of Colorado, Denver

​

Brief Summary: People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions.

​

The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug known to block IFN signaling, in adults with DS and an autoimmune and/or autoinflammatory skin condition. Investigators will also measure the impact of interferon inhibition on a variety of molecular markers, as well as the cognitive abilities and quality of life of participants.

​

Please link complete details: https://clinicaltrials.gov/ct2/show/NCT04246372

​

Location: Aurora, Colorado

​

Contact: Angela Rachubinski, PhD 303-724-7366, DSresearch@ucdenver.edu  

​

Belinda Enriquez Estrada, MS,   303-724-0491 DSresearch@ucdenver.edu

​

Location: Aarhus, Denmark

 

Contact: Kasper F Hjuler, MD PhD +4523882479 kasped@rm.dk or Louise F Møller